Podcast Episodes
Back to SearchEvolving Second-Line Strategies in HER2+ Lung Cancer
Episode 573
Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs …
9 months, 2 weeks ago
First-Line Strategies in HER2+ Lung Cancer
Episode 572
Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and eme…
9 months, 2 weeks ago
Can HER2+ Metastatic Breast Cancer Be Cured?
Episode 571
Drs. Lynce and Waks explore whether advances in HER2-targeted therapy are making metastatic HER2+ breast cancer potentially curable, highlighting lon…
9 months, 3 weeks ago
What the PATINA Trial Teaches Us About Treating HER2+ Breast Cancer
Episode 570
Drs. Waks and Lynce review the PATINA trial, which showed that adding a CDK4/6 inhibitor to HER2-targeted and endocrine therapy improved progression-…
9 months, 3 weeks ago
Could there be a long-awaited breakthrough in first-line therapy for triple-negative breast cancer?
Episode 569
New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with c…
9 months, 3 weeks ago
Early-Stage HER2+ Breast Cancer
Episode 568
Drs. Lynce and Waks discuss advances in early-stage HER2+ breast cancer, focusing on how targeted therapies have transformed outcomes. They explore d…
9 months, 3 weeks ago
Could the choice of diabetes medication change a patient’s cardiovascular risk?
Episode 567
A large real-world study of over 1.2 million adults with type 2 diabetes found that SGLT2 inhibitors and GLP-1 receptor agonists reduced major cardio…
9 months, 4 weeks ago
Do updated COVID vaccines protect U.S. veterans from severe outcomes?
Episode 566
Data in ~300,000 U.S. veterans show the 2024–2025 COVID-19 booster cut COVID-related ED visits (−29%), hospitalizations (−39%), and deaths (−64%) ove…
10 months ago
When can stage II–III colon cancer be considered cured after treatment?
Episode 565
An analysis of 35,000 stage II–III colon cancer cases shows relapse risk peaks in year one and falls below 0.5% per six-month interval by year six, o…
10 months, 1 week ago
ICML 2025: Novel Agents in CLL
Episode 564
Drs. Fahkri and Seshadri review abstracts from the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland, exploring investigatio…
10 months, 2 weeks ago